Pfizer Inc. received approval from the U.S. Food and Drug Administration (FDA) for metastatic non-small cell lung cancer which is the second most common type of cancer in the world.
Sanofi S.A. an innovative global healthcare company announced that it has received approval from the U.S. Food and Drug Administration (FDA) for Dupixent (dupilumab) a monoclonal antibody used to treat allergic conditions such as, asthma. Further, is the first and only biologic drug authorized for the treatment of moderate-to-severe atopic dermatitis, and the children treated with Dupixent with topical corticosteroids (TCS) reported that they had cleaner skin and considerably less itching.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5180
Published Date: Aug 23, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing prevalence of respiratory diseases across the globe and the development of non-invasive diagnostic procedures are the major factors driving the growth of the market.
The market size of Hypersensitivity Pneumonitis is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023 â€“ 2035.
The major players in the market are Svizera Healthcare Pvt. Ltd., Sanofi S.A., Novo Nordisk A/S, Astra Zeneca Plc., Eli lilly and Company, Bayer AG, Sun Pharmaceutical Industries Ltd., Novartis AG.
The corticosteroids segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.